anti-TSLPR CAR T-cell therapy (National Institutes of Health/University of Pennsylvania)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameanti-TSLPR CAR T-cell therapy (National Institutes of Health/University of Pennsylvania)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionCytokine receptor-like factor 2 modulators

TargetsCytokine receptor-like factor 2

Therapy Area/IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesNational Institutes Of Health

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNational Institutes Of Health University Of Pennsylvania

Active IndicationsN/A

Inactive IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A